Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by Wino115on Jan 14, 2021 2:38pm
122 Views
Post# 32298514

RE:RE:RE:RE:RE:RE:Tanguay

RE:RE:RE:RE:RE:RE:TanguayThe question will be, did that offering introduce a compelling idea via the brokers to some smart-money clients who will build and take advantage of possible success and low value versus many comps, or will all those shares just get blown back in to the market because there were a lot of short term flippers in it, clients just listening to brokers and not really doing any due dilly -- in essence, no real long term holders.  We will only find out, but don't be surprised to see more volume being offered and unless they attracted big boys, no more demand than before.  Not even sure the reports will make much of a difference as they never have before. They aren't really credible analysts at this point and with very little following as shown by the evidence of their bullishness but no takers. 


Bucknelly21 wrote: Btw where is the demand for these shares after this deal? Back to poor volume 


<< Previous
Bullboard Posts
Next >>